GE HealthCare Technologies (GEHC) Financials

$75.73 +1.61 (+2.17%)

Closing price 09/5/2025 04:00 PM Eastern

Extended Trading

$75.79 +0.06 (+0.08%)

As of 09/5/2025 08:00 PM Eastern

Annual Income Statements for GE HealthCare Technologies

This table shows GE HealthCare Technologies' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	2,247	1,916	1,385	1,993
Consolidated Net Income / (Loss)	2,293	1,967	1,614	2,050
Net Income / (Loss) Continuing Operations	2,275	1,949	1,618	2,050
Total Pre-Tax Income	2,875	2,512	2,361	2,581
Total Operating Income	2,795	2,522	2,435	2,625
Total Gross Profit	7,174	7,179	7,922	8,205
Total Revenue	17,585	18,341	19,552	19,672
Operating Revenue	17,585	18,341	19,552	19,672
Total Cost of Revenue	10,411	11,162	11,630	11,467
Operating Cost of Revenue	10,411	11,162	11,630	11,467
Total Operating Expenses	4,379	4,657	5,487	5,580
Selling, General & Admin Expense	3,563	3,631	4,282	4,269
Research & Development Expense	816	1,026	1,205	1,311
Total Other Income / (Expense), net	80	-10	-74	-43
Interest Expense	40	77	542	504
Other Income / (Expense), net	120	67	468	461
Income Tax Expense	600	563	743	531
Net Income / (Loss) Discontinued Operations	18	18	-4.00	0.00
Preferred Stock Dividends Declared	0.00	0.00	183	0.00
Net Income / (Loss) Attributable to Noncontrolling Interest	46	51	46	57
Basic Earnings per Share	$4.95	$4.22	$3.05	$4.37
Weighted Average Basic Shares Outstanding	454M	454M	455M	456M
Diluted Earnings per Share	$4.95	$4.22	$3.03	$4.34
Weighted Average Diluted Shares Outstanding	454M	454M	458M	459M
Weighted Average Basic & Diluted Shares Outstanding	-	-	455.36M	457.30M
Cash Dividends to Common per Share	-	-	$0.12	$0.13

This table shows GE HealthCare Technologies' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025
Net Income / (Loss) Attributable to Common Shareholders	-	189	418	375	403	374	428	470	721	564	486
Consolidated Net Income / (Loss)	-	383	433	382	416	388	435	490	737	588	500
Net Income / (Loss) Continuing Operations	-	383	433	386	416	388	435	490	737	588	500
Total Pre-Tax Income	-	546	570	636	609	512	578	658	833	692	613
Total Operating Income	-	559	570	617	689	540	608	676	801	629	654
Total Gross Profit	-	1,891	1,940	1,935	2,156	1,902	2,002	2,026	2,275	2,012	1,985
Total Revenue	-	4,707	4,817	4,822	5,206	4,650	4,839	4,863	5,320	4,777	5,007
Operating Revenue	-	4,707	4,817	4,822	5,206	4,650	4,839	4,863	5,320	4,777	5,007
Total Cost of Revenue	-	2,816	2,877	2,887	3,050	2,749	2,837	2,838	3,043	2,765	3,023
Operating Cost of Revenue	-	2,816	2,877	2,887	3,050	2,749	2,837	2,838	3,043	2,765	3,023
Total Operating Expenses	-	1,332	1,370	1,318	1,467	1,362	1,394	1,350	1,474	1,384	1,331
Selling, General & Admin Expense	-	1,062	1,072	996	1,152	1,038	1,067	1,034	1,130	1,040	1,029
Research & Development Expense	-	270	298	322	315	324	327	316	344	344	302
Total Other Income / (Expense), net	-	-13	0.00	19	-80	-28	-29	-19	33	63	-41
Interest Expense	-	136	137	138	131	122	131	130	121	110	113
Other Income / (Expense), net	-	123	137	157	51	94	102	111	154	173	72
Income Tax Expense	-	163	137	250	193	124	143	168	96	104	113
Net Income / (Loss) Attributable to Noncontrolling Interest	-	11	15	7.00	13	14	7.00	19	17	24	14
Basic Earnings per Share	-	$0.42	$0.92	$0.82	$0.89	$0.82	$0.94	$1.03	$1.58	$1.23	$1.06
Weighted Average Basic Shares Outstanding	454M	454M	455M	455M	455M	456M	457M	457M	456M	457M	457M
Diluted Earnings per Share	-	$0.41	$0.91	$0.82	$0.89	$0.81	$0.93	$1.02	$1.58	$1.23	$1.06
Weighted Average Diluted Shares Outstanding	454M	457M	458M	458M	458M	459M	459M	459M	459M	459M	458M
Weighted Average Basic & Diluted Shares Outstanding	0.00	-	-	455.24M	455.36M	456.47M	456.66M	456.87M	457.30M	457.88M	456.56M

This table details how cash moves in and out of GE HealthCare Technologies' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-451	890	1,055	387
Net Cash From Operating Activities	1,607	2,113	2,101	1,951
Net Cash From Continuing Operating Activities	1,607	2,134	2,101	1,955
Net Income / (Loss) Continuing Operations	2,275	1,949	1,618	2,050
Consolidated Net Income / (Loss)	2,293	1,967	1,614	2,050
Net Income / (Loss) Discontinued Operations	18	18	-4.00	0.00
Depreciation Expense	225	228	248	268
Amortization Expense	400	405	362	312
Non-Cash Adjustments To Reconcile Net Income	45	-263	-390	-585
Changes in Operating Assets and Liabilities, net	-1,338	-185	263	-91
Net Cash From Discontinued Operating Activities	0.00	-21	0.00	-4.00
Net Cash From Investing Activities	-1,761	-398	-558	-914
Net Cash From Continuing Investing Activities	-1,761	-398	-558	-914
Purchase of Property, Plant & Equipment	-248	-310	-387	-401
Acquisitions	-1,481	0.00	-147	-313
Purchase of Investments	-	-59	-48	-40
Sale of Property, Plant & Equipment	15	4.00	1.00	0.00
Other Investing Activities, net	-47	-33	23	-160
Net Cash From Financing Activities	-263	-822	-478	-573
Net Cash From Continuing Financing Activities	-263	-822	-478	-572
Repayment of Debt	-23	-95	-904	-1,452
Repurchase of Common Equity	0.00	0.00	-211	0.00
Payment of Dividends	0.00	0.00	-41	-55
Issuance of Debt	-2.00	8,207	1,994	995
Issuance of Common Equity	-	0.00	34	33
Other Financing Activities, net	-238	-8,934	-1,350	-93
Effect of Exchange Rate Changes	-34	-3.00	-10	-77
Cash Interest Paid	21	0.00	570	550

This table details how cash moves in and out of GE HealthCare Technologies' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025
Net Change in Cash & Equivalents	947	883	-389	475	86	59	-547	1,554	-679	-416	1,289
Net Cash From Operating Activities	1,042	468	-67	650	1,050	419	-119	738	913	250	94
Net Cash From Continuing Operating Activities	1,063	468	-67	650	1,050	419	-121	744	913	250	95
Net Income / (Loss) Continuing Operations	567	383	433	386	416	388	435	489	738	588	500
Consolidated Net Income / (Loss)	573	383	433	382	416	388	435	489	738	588	500
Depreciation Expense	59	61	63	64	60	68	69	66	65	66	72
Amortization Expense	98	96	93	89	84	80	80	77	75	70	76
Non-Cash Adjustments To Reconcile Net Income	-15	-101	-216	-64	-9.00	-105	-202	-91	-137	-230	-185
Changes in Operating Assets and Liabilities, net	354	29	-440	175	499	-12	-503	203	171	-244	-368
Net Cash From Investing Activities	-95	-266	-84	-120	-88	-188	-349	-137	-240	-407	-223
Net Cash From Continuing Investing Activities	-95	-266	-84	-120	-88	-188	-350	-137	-240	-407	-222
Purchase of Property, Plant & Equipment	-77	-143	-70	-80	-94	-145	-64	-90	-102	-152	-86
Acquisitions	-	-127	-20	-	-	0.00	-259	-	-54	-269	-10
Purchase of Investments	-	-	-	-	-27	-19	-	-	-7.00	-20	-8.00
Other Investing Activities, net	40	4.00	5.00	-19	33	-24	-27	-14	-77	34	-118
Net Cash From Financing Activities	-37	673	-227	-24	-900	-153	-57	914	-1,277	-286	1,361
Net Cash From Continuing Financing Activities	-37	673	-227	-24	-900	-153	-57	914	-1,276	-286	1,360
Repayment of Debt	-2.00	-1.00	1.00	-33	-871	-146	-42	-7.00	-1,262	-263	-13
Payment of Dividends	-	0.00	-14	-14	-13	-14	-14	-13	-14	-16	-16
Issuance of Debt	8,196	1,991	-3.00	23	-17	2.00	-1.00	993	1.00	1.00	1,493
Issuance of Common Equity	-	-	-	-	3.00	16	-	-	2.00	20	1.00
Other Financing Activities, net	-8,231	-1,317	-	-31	-2.00	-11	-	-90	-3.00	-28	-5.00
Effect of Exchange Rate Changes	37	8.00	-11	-31	24	-19	-22	39	-75	27	57
Cash Interest Paid	-	42	208	68	252	55	219	65	211	78	182

This table presents GE HealthCare Technologies' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	27,539	32,454	33,089
Total Current Assets	8,318	9,410	9,901
Cash & Equivalents	1,445	2,504	2,889
Accounts Receivable	3,312	3,557	3,566
Inventories, net	2,155	1,960	1,939
Other Current Assets	1,406	1,389	1,506
Plant, Property, & Equipment, net	2,314	2,500	2,550
Total Noncurrent Assets	16,907	20,544	20,638
Goodwill	12,813	12,936	13,136
Intangible Assets	1,520	1,253	1,078
Noncurrent Deferred & Refundable Income Taxes	1,550	4,474	4,474
Other Noncurrent Operating Assets	1,024	1,881	1,950
Total Liabilities & Shareholders' Equity	27,539	32,454	33,089
Total Liabilities	17,947	25,144	24,437
Total Current Liabilities	7,191	8,981	9,553
Short-Term Debt	15	1,006	1,502
Accounts Payable	2,944	2,947	3,035
Current Employee Benefit Liabilities	-	1,518	1,521
Other Current Liabilities	4,232	3,510	3,495
Total Noncurrent Liabilities	10,756	16,163	14,884
Long-Term Debt	8,234	8,436	7,449
Noncurrent Deferred & Payable Income Tax Liabilities	370	68	56
Noncurrent Employee Benefit Liabilities	549	5,782	5,583
Other Noncurrent Operating Liabilities	1,603	1,877	1,796
Commitments & Contingencies	0.00	0.00	0.00
Redeemable Noncontrolling Interest	230	165	188
Total Equity & Noncontrolling Interests	9,362	7,145	8,464
Total Preferred & Common Equity	9,357	7,133	8,446
Total Common Equity	9,357	7,133	8,446
Common Stock	0.00	6,498	6,588
Retained Earnings	0.00	1,326	3,262
Treasury Stock	-	0.00	-25
Accumulated Other Comprehensive Income / (Loss)	-1,878	-691	-1,379
Noncontrolling Interest	5.00	12	18

This table presents GE HealthCare Technologies' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025
Total Assets	27,539	32,637	32,311	32,382	32,454	32,208	31,852	33,855	33,089	33,586	35,500
Total Current Assets	8,318	9,604	9,240	9,468	9,410	9,373	8,806	10,638	9,901	9,735	11,308
Cash & Equivalents	1,445	2,327	1,939	2,418	2,504	2,563	2,015	3,568	2,889	2,473	3,763
Accounts Receivable	3,312	3,404	3,397	3,400	3,557	3,344	3,354	3,424	3,569	3,572	3,562
Inventories, net	2,155	2,256	2,264	2,128	1,960	1,989	2,023	2,124	1,939	2,158	2,283
Other Current Assets	1,406	1,617	1,640	1,522	1,389	1,478	1,414	1,522	1,503	1,532	1,700
Plant, Property, & Equipment, net	2,314	2,327	2,357	2,355	2,500	2,445	2,458	2,539	2,550	2,851	2,962
Total Noncurrent Assets	16,907	20,706	20,802	20,559	20,544	20,392	20,589	20,677	20,638	20,999	21,230
Goodwill	12,813	12,924	12,929	12,914	12,936	12,927	13,116	13,138	13,136	13,373	13,417
Intangible Assets	1,520	1,494	1,423	1,332	1,253	1,174	1,195	1,132	1,078	1,238	1,220
Noncurrent Deferred & Refundable Income Taxes	1,550	4,336	4,349	4,277	4,474	4,413	4,365	4,309	4,474	4,462	4,517
Other Noncurrent Operating Assets	1,024	1,952	2,101	2,036	1,881	1,878	1,913	2,098	1,950	1,926	2,076
Total Liabilities & Shareholders' Equity	27,539	32,637	32,311	32,382	32,454	32,208	31,852	33,855	33,089	33,586	35,500
Total Liabilities	17,947	25,740	24,988	25,079	25,144	24,609	23,858	25,343	24,437	24,168	25,548
Total Current Liabilities	7,191	8,236	7,581	7,565	8,981	8,859	8,318	8,670	9,553	9,969	9,748
Short-Term Debt	15	5.00	5.00	7.00	1,006	1,008	1,007	1,007	1,502	2,002	2,005
Accounts Payable	2,944	3,163	2,835	2,774	2,947	2,931	2,824	2,911	3,022	3,152	2,975
Current Employee Benefit Liabilities	-	-	-	-	1,518	-	1,235	1,422	1,521	1,343	1,364
Other Current Liabilities	4,232	5,068	4,741	4,784	3,510	4,920	3,251	3,331	3,508	3,472	3,405
Total Noncurrent Liabilities	10,756	17,504	17,539	17,514	16,163	15,751	15,539	16,673	14,884	14,199	15,799
Long-Term Debt	8,234	10,234	10,233	10,253	8,436	8,247	8,233	9,306	7,449	6,757	8,270
Noncurrent Deferred & Payable Income Tax Liabilities	370	64	81	62	68	68	55	59	56	159	173
Noncurrent Employee Benefit Liabilities	549	5,372	5,167	5,373	5,782	5,625	5,455	5,388	5,583	5,443	5,351
Other Noncurrent Operating Liabilities	1,603	1,834	2,058	1,826	1,877	1,811	1,796	1,920	1,796	1,840	2,005
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	230	201	209	161	165	177	177	177	188	211	220
Total Equity & Noncontrolling Interests	9,362	6,696	7,114	7,142	7,145	7,423	7,817	8,335	8,464	9,207	9,733
Total Preferred & Common Equity	9,357	6,690	7,102	7,131	7,133	7,408	7,801	8,317	8,446	9,187	9,712
Total Common Equity	9,357	6,690	7,102	7,131	7,133	7,409	7,801	8,318	8,446	9,188	9,713
Common Stock	0.00	6,430	6,456	6,474	6,498	6,509	6,545	6,556	6,588	6,602	6,633
Retained Earnings	0.00	185	576	937	1,326	1,687	2,101	2,558	3,262	3,810	4,295
Treasury Stock	-	-	-	-	0.00	-	-	-25	-25	-25	-125
Accumulated Other Comprehensive Income / (Loss)	-1,878	75	70	-280	-691	-787	-845	-771	-1,379	-1,199	-1,090
Noncontrolling Interest	5.00	6.00	12	11	12	14	16	18	18	20	21

This table displays calculated financial ratios and metrics derived from GE HealthCare Technologies' official financial filings.

Metric	2021	2022	2023	2024
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-
Revenue Growth	0.00%	4.30%	6.60%	0.61%
EBITDA Growth	0.00%	-8.98%	9.03%	4.36%
EBIT Growth	0.00%	-11.18%	12.13%	6.30%
NOPAT Growth	0.00%	-11.53%	-14.72%	24.94%
Net Income Growth	0.00%	-14.22%	-17.95%	27.01%
EPS Growth	0.00%	-14.75%	-28.20%	43.23%
Operating Cash Flow Growth	0.00%	31.49%	-0.57%	-7.14%
Free Cash Flow Firm Growth	0.00%	0.00%	126.43%	-57.56%
Invested Capital Growth	0.00%	0.00%	-13.10%	3.26%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.58%
EBITDA Q/Q Growth	0.00%	0.00%	463.88%	6.11%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	7.49%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	13.10%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	18.57%
EPS Q/Q Growth	0.00%	0.00%	0.00%	18.90%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.38%	-6.56%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-6.55%
Invested Capital Q/Q Growth	0.00%	0.00%	-5.92%	-3.55%
Profitability Metrics	-	-	-	-
Gross Margin	40.80%	39.14%	40.52%	41.71%
EBITDA Margin	20.13%	17.57%	17.97%	18.64%
Operating Margin	15.89%	13.75%	12.45%	13.34%
EBIT Margin	16.58%	14.12%	14.85%	15.69%
Profit (Net Income) Margin	13.04%	10.72%	8.25%	10.42%
Tax Burden Percent	79.76%	78.30%	68.36%	79.43%
Interest Burden Percent	98.63%	97.03%	81.33%	83.64%
Effective Tax Rate	20.87%	22.41%	31.47%	20.57%
Return on Invested Capital (ROIC)	0.00%	23.87%	10.89%	14.40%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	24.17%	10.09%	13.86%
Return on Net Nonoperating Assets (RNNOA)	0.00%	17.14%	8.21%	11.29%
Return on Equity (ROE)	0.00%	41.01%	19.10%	25.69%
Cash Return on Invested Capital (CROIC)	0.00%	-176.13%	24.91%	11.19%
Operating Return on Assets (OROA)	0.00%	9.40%	9.68%	9.42%
Return on Assets (ROA)	0.00%	7.14%	5.38%	6.26%
Return on Common Equity (ROCE)	0.00%	40.01%	18.63%	25.07%
Return on Equity Simple (ROE_SIMPLE)	0.00%	21.02%	22.63%	24.27%
Net Operating Profit after Tax (NOPAT)	2,212	1,957	1,669	2,085
NOPAT Margin	12.58%	10.67%	8.53%	10.60%
Net Nonoperating Expense Percent (NNEP)	0.00%	-0.30%	0.80%	0.54%
Return On Investment Capital (ROIC_SIMPLE)	-	11.11%	10.06%	11.97%
Cost of Revenue to Revenue	59.20%	60.86%	59.48%	58.29%
SG&A Expenses to Revenue	20.26%	19.80%	21.90%	21.70%
R&D to Revenue	4.64%	5.59%	6.16%	6.66%
Operating Expenses to Revenue	24.90%	25.39%	28.06%	28.37%
Earnings before Interest and Taxes (EBIT)	2,915	2,589	2,903	3,086
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	3,540	3,222	3,513	3,666
Valuation Ratios	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	4.91	4.20
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	1.79	1.80
Price to Earnings (P/E)	0.00	0.00	25.29	17.80
Dividend Yield	0.00%	0.00%	0.12%	0.15%
Earnings Yield	0.00%	0.00%	3.95%	5.62%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	2.96	2.84
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	2.16	2.12
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	12.00	11.39
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	14.52	13.53
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	25.26	20.02
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	20.06	21.39
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	11.04	25.77
Leverage & Solvency	-	-	-	-
Debt to Equity	0.00	0.86	1.29	1.03
Long-Term Debt to Equity	0.00	0.86	1.15	0.86
Financial Leverage	0.00	0.71	0.81	0.81
Leverage Ratio	0.00	2.87	3.55	4.11
Compound Leverage Factor	0.00	2.79	2.89	3.43
Debt to Total Capital	0.00%	46.24%	56.36%	50.85%
Short-Term Debt to Total Capital	0.00%	0.08%	6.01%	8.53%
Long-Term Debt to Total Capital	0.00%	46.15%	50.36%	42.32%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	1.32%	1.06%	1.17%
Common Equity to Total Capital	0.00%	52.45%	42.58%	47.98%
Debt to EBITDA	0.00	2.56	2.69	2.44
Net Debt to EBITDA	0.00	2.11	1.98	1.65
Long-Term Debt to EBITDA	0.00	2.56	2.40	2.03
Debt to NOPAT	0.00	4.22	5.66	4.29
Net Debt to NOPAT	0.00	3.48	4.16	2.91
Long-Term Debt to NOPAT	0.00	4.21	5.06	3.57
Altman Z-Score	0.00	0.00	1.81	1.92
Noncontrolling Interest Sharing Ratio	0.00%	2.45%	2.44%	2.40%
Liquidity Ratios	-	-	-	-
Current Ratio	0.00	1.16	1.05	1.04
Quick Ratio	0.00	0.66	0.67	0.68
Cash Flow Metrics	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-14,439	3,817	1,620
Operating Cash Flow to CapEx	689.70%	690.52%	544.30%	486.53%
Free Cash Flow to Firm to Interest Expense	0.00	-187.52	7.04	3.21
Operating Cash Flow to Interest Expense	40.18	27.44	3.88	3.87
Operating Cash Flow Less CapEx to Interest Expense	34.35	23.47	3.16	3.08
Efficiency Ratios	-	-	-	-
Asset Turnover	0.00	0.67	0.65	0.60
Accounts Receivable Turnover	0.00	5.54	5.69	5.52
Inventory Turnover	0.00	5.18	5.65	5.88
Fixed Asset Turnover	0.00	7.93	8.12	7.79
Accounts Payable Turnover	0.00	3.79	3.95	3.84
Days Sales Outstanding (DSO)	0.00	65.91	64.12	66.11
Days Inventory Outstanding (DIO)	0.00	70.47	64.57	62.05
Days Payable Outstanding (DPO)	0.00	96.27	92.44	95.00
Cash Conversion Cycle (CCC)	0.00	40.11	36.25	33.16
Capital & Investment Metrics	-	-	-	-
Invested Capital	0.00	16,396	14,248	14,713
Invested Capital Turnover	0.00	2.24	1.28	1.36
Increase / (Decrease) in Invested Capital	0.00	16,396	-2,148	465
Enterprise Value (EV)	0.00	0.00	42,147	41,741
Market Capitalization	0.00	0.00	35,032	35,473
Book Value per Share	$0.00	$20.61	$15.67	$18.49
Tangible Book Value per Share	$0.00	($10.96)	($15.50)	($12.63)
Total Capital	0.00	17,841	16,752	17,603
Total Debt	0.00	8,249	9,442	8,951
Total Long-Term Debt	0.00	8,234	8,436	7,449
Net Debt	0.00	6,804	6,938	6,062
Capital Expenditures (CapEx)	233	306	386	401
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-303	-1,069	-1,039
Debt-free Net Working Capital (DFNWC)	0.00	1,142	1,435	1,850
Net Working Capital (NWC)	0.00	1,127	429	348
Net Nonoperating Expense (NNE)	-81	-10	55	35
Net Nonoperating Obligations (NNO)	0.00	6,804	6,938	6,061
Total Depreciation and Amortization (D&A)	625	633	610	580
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-1.65%	-5.47%	-5.28%
Debt-free Net Working Capital to Revenue	0.00%	6.23%	7.34%	9.40%
Net Working Capital to Revenue	0.00%	6.14%	2.19%	1.77%
Earnings Adjustments	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$3.05	$4.37
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	455M	456M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$3.03	$4.34
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	458M	459M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	455.36M	457.30M
Normalized Net Operating Profit after Tax (NOPAT)	2,212	1,957	1,669	2,085
Normalized NOPAT Margin	12.58%	10.67%	8.53%	10.60%
Pre Tax Income Margin	16.35%	13.70%	12.08%	13.12%
Debt Service Ratios	-	-	-	-
EBIT to Interest Expense	72.88	33.62	5.36	6.12
NOPAT to Interest Expense	55.29	25.41	3.08	4.14
EBIT Less CapEx to Interest Expense	67.05	29.65	4.64	5.33
NOPAT Less CapEx to Interest Expense	49.47	21.44	2.37	3.34
Payout Ratios	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	2.54%	2.68%
Augmented Payout Ratio	0.00%	0.00%	15.61%	2.68%

This table displays calculated financial ratios and metrics derived from GE HealthCare Technologies' official financial filings.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	5.38%	0.00%	-1.21%	0.46%	0.85%	2.19%	2.73%	3.47%
EBITDA Growth	0.00%	0.00%	0.00%	48.56%	463.06%	-6.79%	-0.46%	0.32%	23.87%	19.95%	1.75%
EBIT Growth	0.00%	0.00%	0.00%	24.04%	0.00%	-7.04%	0.42%	1.68%	29.05%	26.50%	2.25%
NOPAT Growth	0.00%	0.00%	0.00%	-21.91%	0.00%	4.36%	5.68%	34.43%	50.58%	30.61%	16.58%
Net Income Growth	0.00%	0.00%	0.00%	-22.52%	0.00%	1.31%	0.46%	28.27%	77.16%	51.55%	14.94%
EPS Growth	0.00%	0.00%	0.00%	-23.36%	0.00%	97.56%	2.20%	24.39%	77.53%	51.85%	13.98%
Operating Cash Flow Growth	0.00%	0.00%	0.00%	0.00%	0.77%	-10.47%	-77.61%	13.54%	-13.05%	-40.33%	178.99%
Free Cash Flow Firm Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	102.66%	-90.69%	93.69%	95.20%
Invested Capital Growth	0.00%	0.00%	0.00%	0.00%	-13.10%	0.00%	0.00%	0.73%	3.26%	9.87%	8.16%
Revenue Q/Q Growth	0.00%	0.00%	2.34%	0.10%	7.96%	0.00%	4.06%	0.50%	9.40%	-10.21%	4.81%
EBITDA Q/Q Growth	-74.84%	434.39%	2.86%	7.42%	-4.64%	443.06%	9.85%	8.27%	17.74%	-14.34%	-6.82%
EBIT Q/Q Growth	-100.00%	0.00%	3.67%	9.48%	-4.39%	0.00%	11.99%	10.85%	21.35%	-16.02%	-9.48%
NOPAT Q/Q Growth	-100.00%	0.00%	10.43%	-13.52%	25.68%	0.00%	11.82%	10.02%	40.78%	-24.58%	-0.19%
Net Income Q/Q Growth	0.00%	0.00%	13.05%	-11.78%	8.90%	0.00%	12.11%	12.64%	50.41%	-20.22%	-14.97%
EPS Q/Q Growth	0.00%	0.00%	121.95%	-9.89%	8.54%	0.00%	14.81%	9.68%	54.90%	-22.15%	-13.82%
Operating Cash Flow Q/Q Growth	0.00%	-55.09%	-114.32%	1,070.15%	61.54%	-60.10%	-128.40%	720.17%	23.71%	-72.62%	-62.40%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	117.73%	-746.36%	-6.34%	102.66%	-38.06%	-459.28%	19.07%
Invested Capital Q/Q Growth	0.00%	-100.00%	0.00%	0.00%	-5.92%	0.32%	6.50%	0.22%	-3.55%	6.73%	4.85%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	40.17%	40.27%	40.13%	41.41%	40.90%	41.37%	41.66%	42.76%	42.12%	39.64%
EBITDA Margin	0.00%	17.82%	17.92%	19.22%	16.98%	16.82%	17.75%	19.12%	20.58%	19.64%	17.46%
Operating Margin	0.00%	11.88%	11.83%	12.80%	13.23%	11.61%	12.56%	13.90%	15.06%	13.17%	13.06%
EBIT Margin	0.00%	14.49%	14.68%	16.05%	14.21%	13.63%	14.67%	16.18%	17.95%	16.79%	14.50%
Profit (Net Income) Margin	0.00%	8.14%	8.99%	7.92%	7.99%	8.34%	8.99%	10.08%	13.85%	12.31%	9.99%
Tax Burden Percent	0.00%	70.15%	75.96%	60.06%	68.31%	75.78%	75.26%	74.47%	88.48%	84.97%	81.57%
Interest Burden Percent	0.00%	80.06%	80.62%	82.17%	82.30%	80.76%	81.41%	83.61%	87.23%	86.28%	84.44%
Effective Tax Rate	0.00%	29.85%	24.04%	39.31%	31.69%	24.22%	24.74%	25.53%	11.52%	15.03%	18.43%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	11.54%	24.01%	24.25%	13.32%	18.10%	14.77%	13.43%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	10.74%	23.37%	23.62%	13.14%	18.53%	15.59%	12.94%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	8.73%	20.58%	21.36%	12.11%	15.09%	11.89%	9.91%
Return on Equity (ROE)	0.00%	0.00%	0.00%	0.00%	20.27%	44.59%	45.61%	25.43%	33.19%	26.66%	23.33%
Cash Return on Invested Capital (CROIC)	-88.07%	0.00%	0.00%	0.00%	24.91%	-176.42%	-177.56%	11.40%	11.19%	5.35%	6.58%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	9.27%	16.51%	17.98%	9.56%	10.78%	10.10%	8.60%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	5.21%	10.10%	11.02%	5.95%	8.32%	7.41%	5.92%
Return on Common Equity (ROCE)	0.00%	0.00%	0.00%	0.00%	19.78%	43.47%	44.51%	24.85%	32.39%	26.00%	22.77%
Return on Equity Simple (ROE_SIMPLE)	0.00%	0.00%	0.00%	0.00%	0.00%	21.85%	20.78%	20.79%	0.00%	24.49%	0.00%
Net Operating Profit after Tax (NOPAT)	0.00	392	433	374	471	409	458	503	709	534	533
NOPAT Margin	0.00%	8.33%	8.99%	7.77%	9.04%	8.80%	9.46%	10.35%	13.32%	11.19%	10.65%
Net Nonoperating Expense Percent (NNEP)	0.00%	0.00%	0.00%	-0.19%	0.80%	0.63%	0.62%	0.18%	-0.44%	-0.83%	0.49%
Return On Investment Capital (ROIC_SIMPLE)	0.00%	-	-	-	2.84%	-	-	-	4.07%	2.97%	2.67%
Cost of Revenue to Revenue	0.00%	59.83%	59.73%	59.87%	58.59%	59.12%	58.63%	58.36%	57.20%	57.88%	60.38%
SG&A Expenses to Revenue	0.00%	22.56%	22.25%	20.66%	22.13%	22.32%	22.05%	21.26%	21.24%	21.77%	20.55%
R&D to Revenue	0.00%	5.74%	6.19%	6.68%	6.05%	6.97%	6.76%	6.50%	6.47%	7.20%	6.03%
Operating Expenses to Revenue	0.00%	28.30%	28.44%	27.33%	28.18%	29.29%	28.81%	27.76%	27.71%	28.97%	26.58%
Earnings before Interest and Taxes (EBIT)	0.00	682	707	774	740	634	710	787	955	802	726
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	157	839	863	927	884	782	859	930	1,095	938	874
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	4.32	4.91	5.57	4.53	5.12	4.20	3.99	3.46
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	1.79	2.12	1.81	2.18	1.80	1.85	1.68
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	25.29	26.28	22.38	25.43	17.80	16.77	15.00
Dividend Yield	0.00%	0.00%	0.04%	0.09%	0.12%	0.13%	0.19%	0.13%	0.15%	0.16%	0.18%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	3.95%	3.81%	4.47%	3.93%	5.62%	5.96%	6.67%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	2.56	2.96	3.37	2.81	3.25	2.84	2.75	2.45
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	2.16	2.47	2.19	2.53	2.12	2.18	2.02
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	62.34	12.00	13.93	12.39	14.33	11.39	11.29	10.52
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	14.52	16.86	14.97	17.25	13.53	13.26	12.34
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	25.26	28.57	25.05	26.87	20.02	19.50	17.66
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	18.56	20.06	23.46	21.39	23.72	21.39	24.21	20.23
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	11.04	0.00	0.00	28.57	25.77	53.80	38.69
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.86	0.00	0.00	1.40	1.29	1.22	1.16	1.21	1.03	0.93	1.03
Long-Term Debt to Equity	0.86	0.00	0.00	1.40	1.15	1.09	1.03	1.09	0.86	0.72	0.83
Financial Leverage	0.71	0.00	0.00	1.07	0.81	0.88	0.90	0.92	0.81	0.76	0.77
Leverage Ratio	2.87	0.00	0.00	4.43	3.55	4.24	3.98	4.19	4.11	3.87	3.75
Compound Leverage Factor	0.00	0.00	0.00	3.64	2.92	3.42	3.24	3.50	3.58	3.34	3.17
Debt to Total Capital	46.24%	0.00%	0.00%	58.42%	56.36%	54.91%	53.61%	54.78%	50.85%	48.19%	50.80%
Short-Term Debt to Total Capital	0.08%	0.00%	0.00%	0.04%	6.01%	5.98%	5.84%	5.35%	8.53%	11.01%	9.91%
Long-Term Debt to Total Capital	46.15%	0.00%	0.00%	58.38%	50.36%	48.93%	47.77%	49.43%	42.32%	37.17%	40.88%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	1.32%	0.00%	0.00%	0.98%	1.06%	1.13%	1.12%	1.04%	1.17%	1.27%	1.19%
Common Equity to Total Capital	52.45%	0.00%	0.00%	40.60%	42.58%	43.96%	45.27%	44.19%	47.98%	50.55%	48.02%
Debt to EBITDA	2.56	0.00	0.00	16.47	2.69	2.68	2.68	2.98	2.44	2.29	2.68
Net Debt to EBITDA	2.11	0.00	0.00	12.59	1.98	1.94	2.09	1.95	1.65	1.64	1.70
Long-Term Debt to EBITDA	2.56	0.00	0.00	16.46	2.40	2.39	2.39	2.69	2.03	1.77	2.16
Debt to NOPAT	4.22	0.00	0.00	0.00	5.66	5.49	5.41	5.59	4.29	3.96	4.50
Net Debt to NOPAT	3.48	0.00	0.00	0.00	4.16	3.97	4.23	3.66	2.91	2.84	2.85
Long-Term Debt to NOPAT	4.21	0.00	0.00	0.00	5.06	4.89	4.82	5.05	3.57	3.06	3.62
Altman Z-Score	0.00	0.00	0.00	0.93	1.59	1.77	1.69	1.84	1.71	1.73	1.64
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	2.36%	2.44%	2.51%	2.41%	2.31%	2.40%	2.47%	2.41%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.16	0.00	0.00	1.25	1.05	1.06	1.06	1.23	1.04	0.98	1.16
Quick Ratio	0.66	0.00	0.00	0.77	0.67	0.67	0.65	0.81	0.68	0.61	0.75
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	0.00	0.00	-14,771	2,619	-13,884	-14,764	393	244	-876	-709
Operating Cash Flow to CapEx	1,371.05%	327.27%	-95.71%	812.50%	1,117.02%	288.97%	-185.94%	820.00%	895.10%	164.47%	109.30%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	-107.03	19.99	-113.80	-112.71	3.03	2.01	-7.96	-6.27
Operating Cash Flow to Interest Expense	0.00	3.44	-0.49	4.71	8.02	3.43	-0.91	5.68	7.55	2.27	0.83
Operating Cash Flow Less CapEx to Interest Expense	0.00	2.39	-1.00	4.13	7.30	2.25	-1.40	4.98	6.70	0.89	0.07
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.67	0.00	0.00	0.00	0.65	1.21	1.23	0.59	0.60	0.60	0.59
Accounts Receivable Turnover	5.54	0.00	0.00	0.00	5.69	0.00	0.00	5.73	5.52	5.73	5.77
Inventory Turnover	5.18	0.00	0.00	0.00	5.65	0.00	0.00	5.40	5.88	5.54	5.42
Fixed Asset Turnover	7.93	0.00	0.00	0.00	8.12	0.00	0.00	7.99	7.79	7.48	7.37
Accounts Payable Turnover	3.79	0.00	0.00	0.00	3.95	0.00	0.00	4.04	3.84	3.78	4.02
Days Sales Outstanding (DSO)	65.91	0.00	0.00	0.00	64.12	0.00	0.00	63.68	66.11	63.75	63.21
Days Inventory Outstanding (DIO)	70.47	0.00	0.00	0.00	64.57	0.00	0.00	67.63	62.05	65.91	67.34
Days Payable Outstanding (DPO)	96.27	0.00	0.00	0.00	92.44	0.00	0.00	90.42	95.00	96.68	90.69
Cash Conversion Cycle (CCC)	40.11	0.00	0.00	0.00	36.25	0.00	0.00	40.88	33.16	32.98	39.86
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	16,396	0.00	0.00	15,145	14,248	14,293	15,222	15,255	14,713	15,703	16,464
Invested Capital Turnover	1.12	0.00	0.00	0.00	1.28	2.73	2.56	1.29	1.36	1.32	1.26
Increase / (Decrease) in Invested Capital	0.00	0.00	0.00	15,145	-2,148	14,293	15,222	110	465	1,410	1,242
Enterprise Value (EV)	0.00	37,163	36,805	38,840	42,147	48,135	42,775	49,527	41,741	43,134	40,360
Market Capitalization	0.00	37,163	36,805	30,826	35,032	41,252	35,357	42,587	35,473	36,617	33,607
Book Value per Share	$20.61	$0.00	$0.00	$15.67	$15.67	$16.25	$17.09	$18.21	$18.49	$20.09	$21.21
Tangible Book Value per Share	($10.96)	$0.00	$0.00	($15.64)	($15.50)	($14.68)	($14.26)	($13.03)	($12.63)	($11.86)	($10.75)
Total Capital	17,841	0.00	0.00	17,563	16,752	16,855	17,234	18,825	17,603	18,177	20,228
Total Debt	8,249	0.00	0.00	10,260	9,442	9,255	9,240	10,313	8,951	8,759	10,275
Total Long-Term Debt	8,234	0.00	0.00	10,253	8,436	8,247	8,233	9,306	7,449	6,757	8,270
Net Debt	6,804	0.00	0.00	7,842	6,938	6,692	7,225	6,745	6,062	6,286	6,512
Capital Expenditures (CapEx)	76	143	70	80	94	145	64	90	102	152	86
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-303	0.00	0.00	-508	-1,069	-1,041	-520	-593	-1,039	-705	-198
Debt-free Net Working Capital (DFNWC)	1,142	0.00	0.00	1,910	1,435	1,522	1,495	2,975	1,850	1,768	3,565
Net Working Capital (NWC)	1,127	0.00	0.00	1,903	429	514	488	1,968	348	-234	1,560
Net Nonoperating Expense (NNE)	0.00	9.12	0.00	-7.53	55	21	23	13	-28	-54	33
Net Nonoperating Obligations (NNO)	6,804	0.00	0.00	7,842	6,938	6,693	7,228	6,743	6,061	6,285	6,511
Total Depreciation and Amortization (D&A)	157	157	156	153	144	148	149	143	140	136	148
Debt-free, Cash-free Net Working Capital to Revenue	-1.65%	0.00%	0.00%	0.00%	-5.47%	-5.34%	-2.66%	-3.03%	-5.28%	-3.56%	-0.99%
Debt-free Net Working Capital to Revenue	6.23%	0.00%	0.00%	0.00%	7.34%	7.81%	7.66%	15.21%	9.40%	8.93%	17.85%
Net Working Capital to Revenue	6.14%	0.00%	0.00%	0.00%	2.19%	2.64%	2.50%	10.06%	1.77%	-1.18%	7.81%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.82	$0.89	$0.82	$0.94	$1.03	$1.58	$1.23	$1.06
Adjusted Weighted Average Basic Shares Outstanding	454M	0.00	0.00	455M	455M	456M	457M	457M	456M	457M	457M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.82	$0.89	$0.81	$0.93	$1.02	$1.58	$1.23	$1.06
Adjusted Weighted Average Diluted Shares Outstanding	454M	0.00	0.00	458M	458M	459M	459M	459M	459M	459M	458M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	0.00	455.24M	455.36M	456.47M	456.66M	456.87M	457.30M	457.88M	456.56M
Normalized Net Operating Profit after Tax (NOPAT)	0.00	392	433	374	471	409	458	503	709	534	533
Normalized NOPAT Margin	0.00%	8.33%	8.99%	7.77%	9.04%	8.80%	9.46%	10.35%	13.32%	11.19%	10.65%
Pre Tax Income Margin	0.00%	11.60%	11.83%	13.19%	11.70%	11.01%	11.94%	13.53%	15.66%	14.49%	12.24%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	5.01	5.16	5.61	5.65	5.20	5.42	6.05	7.89	7.29	6.42
NOPAT to Interest Expense	0.00	2.88	3.16	2.71	3.59	3.35	3.49	3.87	5.86	4.86	4.72
EBIT Less CapEx to Interest Expense	0.00	3.96	4.65	5.03	4.93	4.01	4.93	5.36	7.05	5.91	5.66
NOPAT Less CapEx to Interest Expense	0.00	1.83	2.65	2.13	2.88	2.17	3.00	3.18	5.01	3.48	3.96
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	2.54%	3.40%	3.39%	3.12%	2.68%	2.53%	2.55%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	15.61%	3.40%	3.39%	3.12%	2.68%	2.53%	6.87%

Key Financial Trends

GE HealthCare Technologies (NASDAQ: GEHC) Financial Overview (Q2 2025 compared to prior quarters and years)

GE HealthCare Technologies delivered mixed financial results in the latest quarter ending June 30, 2025, with some positive revenue growth and earnings, but notable cash flow and leverage concerns. Below is an analysis focusing on key financial metrics and trends over recent quarters and historically.

Operating Revenue for Q2 2025 increased to $5.01 billion from $4.78 billion in Q1 2025, indicating steady top-line growth.
Net Income for Q2 2025 was $500 million, a strong profit, albeit slightly down from $588 million in Q1 2025, reflecting solid profitability.
Total Common Equity rose to $9.71 billion in Q2 2025 from $9.19 billion in Q1 2025, suggesting strengthening shareholder equity.
Cash & Equivalents increased significantly to $3.76 billion at Q2 2025, up from $2.47 billion in Q1 2025, indicating improved liquidity position.

Gross Profit margin slightly decreased; total gross profit was $1.985 billion in Q2 2025 compared to $2.012 billion in Q1 2025, indicating stable but mildly pressured margins.
Operating expenses remain fairly consistent quarter-over-quarter with Selling, General & Admin expense near $1.03 billion and R&D near $302 million, reflecting steady investment in operations and innovation.
Weighted Average Diluted Shares Outstanding remained stable around 457-458 million shares between Q1 and Q2 2025, indicating no significant dilution.
Depreciation and Amortization expenses totaled approximately $148 million in Q2 2025, indicating ongoing investment in fixed and intangible assets.

Net cash from operating activities drastically fell to $94 million in Q2 2025 from $250 million in Q1 2025, signaling slowdown in cash generation from core business.
Net cash used in investing activities increased to -$223 million in Q2 2025 from -$407 million in Q1 2025, driven by acquisitions and property purchases, which could pressure near-term cash flow.
Significant increase in debt issuance of $1.493 billion in Q2 2025, far exceeding debt repayments ($13 million), resulting in higher leverage and potential future interest expense burden.
Total liabilities rose sharply to $25.55 billion in Q2 2025 from $24.17 billion in Q1 2025, primarily due to debt and current liabilities increases.
Interest expense remains elevated at $113 million in Q2 2025 with cash interest paid at $182 million, potentially impacting net income if debt levels persist.
Net cash from financing activities swung sharply positive to $1.36 billion in Q2 2025 from negative $286 million in Q1 2025 reflecting new debt issuance but reducing financial flexibility.

Trends and Context:

Over the past year, revenues have shown a steady upward trend from about $4.7 billion in Q1 2023 to $5 billion in Q2 2025, reflecting gradual growth in healthcare technology demand.
Profitability has remained positive throughout, with net income fluctuating between $383 million and $738 million quarterly, suggesting stable earnings generation.
Cash flow volatility is noticeable, with operating cash flow swinging between negative and positive quarters, potentially reflecting working capital management challenges.
Increasing debt levels and interest costs pose risks to financial health, potentially necessitating heightened focus on deleveraging and cash flow improvement in upcoming quarters.

Summary:

GE HealthCare Technologies shows promising revenue growth and maintains profitability with a solid equity base and improved cash balances in Q2 2025. However, the company faces challenges related to shrinking operating cash flow, increased investing outflows, and significantly higher debt issuance. Retail investors should monitor the company's ability to stabilize cash flow and manage debt levels to sustain long-term financial health amid a growing but capital-intensive market environment.

09/07/25 03:58 AM ETAI Generated. May Contain Errors.

Financials Breakdown Chart

Frequently Asked Questions About GE HealthCare Technologies' Financials

When does GE HealthCare Technologies' financial year end?

According to the most recent income statement we have on file, GE HealthCare Technologies' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has GE HealthCare Technologies' net income changed over the last 3 years?

GE HealthCare Technologies' net income appears to be on a downward trend, with a most recent value of $2.05 billion in 2024, falling from $2.29 billion in 2021. The previous period was $1.61 billion in 2023. Find out what analysts predict for GE HealthCare Technologies in the coming months.

What is GE HealthCare Technologies' operating income?

GE HealthCare Technologies' total operating income in 2024 was $2.63 billion, based on the following breakdown:

Total Gross Profit: $8.21 billion
Total Operating Expenses: $5.58 billion

How has GE HealthCare Technologies' revenue changed over the last 3 years?

Over the last 3 years, GE HealthCare Technologies' total revenue changed from $17.59 billion in 2021 to $19.67 billion in 2024, a change of 11.9%.

How much debt does GE HealthCare Technologies have?

GE HealthCare Technologies' total liabilities were at $24.44 billion at the end of 2024, a 2.8% decrease from 2023, and a 36.2% increase since 2022.

How much cash does GE HealthCare Technologies have?

In the past 2 years, GE HealthCare Technologies' cash and equivalents has ranged from $1.45 billion in 2022 to $2.89 billion in 2024, and is currently $2.89 billion as of their latest financial filing in 2024.

How has GE HealthCare Technologies' book value per share changed over the last 3 years?

Over the last 3 years, GE HealthCare Technologies' book value per share changed from 0.00 in 2021 to 18.49 in 2024, a change of 1,848.7%.

Related Companies

This page (NASDAQ:GEHC) was last updated on 9/7/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GE HealthCare Technologies (GEHC) Financials

Key Financial Trends

Financials Breakdown Chart

Frequently Asked Questions About GE HealthCare Technologies' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GE HealthCare Technologies (GEHC) Financials

Annual Income Statements for GE HealthCare Technologies

Quarterly Income Statements for GE HealthCare Technologies

Annual Cash Flow Statements for GE HealthCare Technologies

Quarterly Cash Flow Statements for GE HealthCare Technologies

Annual Balance Sheets for GE HealthCare Technologies

Quarterly Balance Sheets for GE HealthCare Technologies

Annual Metrics And Ratios for GE HealthCare Technologies

Quarterly Metrics And Ratios for GE HealthCare Technologies

Key Financial Trends

Financials Breakdown Chart

Frequently Asked Questions About GE HealthCare Technologies' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools